RTP Mobile Logo
Consensus or Controversy? Clinical Investigator Perspectives on the Current and Future Management of Mantle Cell, Diffuse Large B-Cell and Hodgkin Lymphoma (Webinar Audio Proceedings)
Released September 2021

Featuring perspectives from Drs Stephen M Ansell, Craig Moskowitz and Laurie H Sehn. Published September 10, 2021. (Webinar Audio Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

    LEARNING OBJECTIVES

    • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of each in clinical practice.
    • Understand the mechanism of action of tafasitamab, and appreciate available research data with this novel anti-CD19 antibody in combination with lenalidomide for patients with relapsed/refractory (R/R) DLBCL.
    • Consider patient age, performance status and other clinical and biologic factors in the up-front and subsequent treatment of mantle cell lymphoma (MCL).
    • Describe the biologic rationale for, available data with and current clinical role of Bruton tyrosine kinase inhibition for patients with R/R MCL, and discern how these agents can be appropriately and safely integrated into routine practice.
    • Evaluate recent data with brexucabtagene autoleucel for R/R MCL, and develop an understanding of how this novel therapy can be employed in patient care.
    • Consider clinical, biologic and patient-related factors in the selection of first-line therapy for individuals with newly diagnosed classical Hodgkin lymphoma (HL).
    • Develop a long-term care plan for patients with R/R HL, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and personal goals for treatment.
    • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, MCL and DLBCL, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOLymphomas21/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/ASCOLymphomas21/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOLymphomas21/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/ASCOLymphomas21.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Stephen M Ansell, MD, PhD
    Professor of Medicine
    Chair, Lymphoma Group
    Mayo Clinic
    Rochester, Minnesota

    Contracted Research (to Institution): ADC Therapeutics, Affimed, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc, Seagen Inc, Takeda Oncology, Trillium Therapeutics Inc.

    Craig Moskowitz, MD
    Physician in Chief, Oncology Service Line
    Sylvester Comprehensive Cancer Center
    Professor of Medicine, Miller School of Medicine
    University of Miami Health System
    Miami, Florida

    No relevant conflicts of interest to disclose.

    Laurie H Sehn, MD, MPH
    Chair, Lymphoma Tumour Group
    BC Cancer Centre for Lymphoid Cancer
    Clinical Professor of Medicine
    Division of Medical Oncology
    University of British Columbia
    Associate Editor, Blood
    Vancouver, British Columbia, Canada

    Advisory Committee and Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Amgen Inc, Apobiologix, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lundbeck, Merck, MorphoSys, Novartis, Pfizer Inc, Roche Laboratories Inc, Sandoz Inc, a Novartis Division, Seagen Inc, Takeda Oncology, Teva Oncology, Verastem Inc; Contracted Research: Teva Oncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Oncopeptides, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Sanofi Genzyme, Seagen Inc, and Takeda Oncology.

    Release date: September 2021
    Expiration date: September 2022

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):